Holen Sie sich die Stockscreener-App
2.19
1.86%
0.04
Handel nachbörslich:
2.19
Schlusskurs vom Vortag:
$2.15
Offen:
$2.17
24-Stunden-Volumen:
1.24M
Relative Volume:
2.21
Marktkapitalisierung:
$288.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-101.70M
KGV:
-1.155
EPS:
-1.8961
Netto-Cashflow:
$-84.35M
1W Leistung:
+8.42%
1M Leistung:
-15.77%
6M Leistung:
+80.99%
1J Leistung:
+183.79%
1-Tages-Spanne:
$2.04
$2.27
1-Wochen-Bereich:
$1.96
$2.27
52-Wochen-Spanne:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Firmenname
Alx Oncology Holdings Inc
Sektor
Branche
Telefon
650-466-7125
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.19 | 282.96M | 0 | -101.70M | -84.35M | -1.8961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Fortgesetzt | UBS | Buy |
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-06 | Eingeleitet | UBS | Buy |
| 2021-02-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-11 | Eingeleitet | Jefferies | Buy |
| 2020-08-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
ALXO: Wells Fargo Initiates Coverage with Overweight Rating | ALXO Stock News - GuruFocus
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO) - MarketBeat
Wells Fargo initiates ALX Oncology stock with overweight rating By Investing.com - Investing.com Canada
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Block Trades: Can ALX Oncology Holdings Inc reach all time highs this yearEarnings Recap Summary & Stock Portfolio Risk Control - baoquankhu1.vn
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - TradingView
IBRX Stock Jumps on Progress in NK Cell Therapy Production - TradingView
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study - TradingView
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - TipRanks
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Finviz
ALX Oncology 2025 Annual Report: Evorpacept Clinical Trials, Pipeline Strategy, and CD47 Blockade Advancements - Minichart
ALX Oncology's (ALXO) Buy Rating Reiterated at HC Wainwright - MarketBeat
ALXO: HC Wainwright Reiterates Buy Rating with Price Target at $4.00 | ALXO Stock News - GuruFocus
ALX Oncology Q4 2025 Earnings Call Transcript - MarketBeat
ALX 2025 10-K: Net loss $101.7M, EPS $(1.90); operating loss $(104.0)M - TradingView
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study - Finviz
Aug Momentum: What is ALX Oncology Holdings Incs book value per share2026 AllTime Highs & Low Risk High Win Rate Picks - baoquankhu1.vn
Alx Oncology Earnings Call Highlights Biomarker Momentum - TipRanks
ALX Oncology initiated with a Buy at UBS - Yahoo Finance
Aug Retail: Does ALX Oncology Holdings Inc stock have upside surprise potentialWatch List & Consistent Income Trade Ideas - baoquankhu1.vn
ALX Oncology (NASDAQ:ALXO) Coverage Initiated by Analysts at UBS Group - MarketBeat
QURE Stock Crashes 32% in a Week: Here's What You Should Know - Finviz
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - TradingView
Mirum Completes Enrollment & Screening in Liver Disease Studies - Finviz
Barbara Klencke (NASDAQ: ALXO) reports option and stock holdings - Stock Titan
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - The Globe and Mail
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update - MarketBeat
Pharma News: Can Piedmont Office Realty Trust Inc grow without external fundingStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
ALX Oncology Q4 Earnings Call Highlights - Defense World
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - marketscreener.com
ALXO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO) - Seeking Alpha
Earnings Scheduled For February 27, 2026 - Sahm
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q4 2025 Earnings Call Transcript - Insider Monkey
ALXO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ALXO's Progress in Clinical Trials and Financial Strength - GuruFocus
ALX Oncology (NASDAQ:ALXO) Posts Earnings Results - MarketBeat
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... By GuruFocus - Investing.com Canada
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... - Yahoo Finance
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology (ALXO) Q4 2025 Earnings Transcript - AOL.com
Earnings call transcript: ALX Oncology Q4 2025 misses EPS forecast, stock dips - Investing.com Canada
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal data ahead - TradingView
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal trial readiness - TradingView
Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):